According to Vaxart's latest financial reports the company's current earnings (TTM) are -$82.21 M. In 2022 the company made an earning of -$0.11 B a decrease over its 2021 earnings that were of -$70.37 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$82.21 M | -23.67% |
2022 | -$0.11 B | 53.05% |
2021 | -$70.37 M | 120.01% |
2020 | -$31.99 M | 76.16% |
2019 | -$18.16 M | 1.44% |
2018 | -$17.9 M | -4.29% |
2017 | -$18.7 M | -40.06% |
2016 | -$31.2 M | -2.19% |
2015 | -$31.9 M | 319.74% |
2014 | -$7.6 M | -25.37% |
2013 | -$10.19 M | 148.49% |
2012 | -$4.1 M | -57.4% |
2011 | -$9.62 M | 810.89% |
2010 | -$1.06 M | -94.36% |
2009 | -$18.73 M | 5.65% |
2008 | -$17.73 M | -59.66% |
2007 | -$43.95 M | -18.43% |
2006 | -$53.88 M | -58.15% |
2005 | -$0.13 B | 221.93% |
2004 | -$40 M | 197.62% |
2003 | -$13.44 M | -603.26% |
2002 | $2.67 M | -97.7% |
2001 | $0.11 B |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | -$2.17 M | -97.37% | Bahamas |
NRC Health
NRC | $40.82 M | -149.66% | ๐บ๐ธ USA |